We evaluated the effects of BI703704, a soluble guanylate cyclase (sGC) activator, EX76637, a sGC stimulator, and EX77619, a phosphodiesterase type 5 (PDE5) inhibitor on the progression of diabetic nephropathy in obese ZSF1 rats. Here, SGCB is linked to diabetic kidney disease.